Administered via intravenous infusion in combination with anti-PD1 antibody: In animal models, this combination therapy effectively converted the tumor microenvironment from an immunologically “cold” to “hot” phenotype, markedly promoting CD8+ T cell infiltration and inducing durable tumor regression. Here, CD8A is linked to neoplasm.